Medigen Biotechnology Corp. (TPEX:3176)

Medigen Biotechnology Income Statement

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	1,621	1,373	1,158	1,056	3,922	615.54
Revenue Growth (YoY)	30.20%	18.57%	9.64%	-73.08%	537.16%	11.44%
Cost of Revenue	650	618.94	540.39	968.49	1,371	351.89
Gross Profit	970.75	753.76	617.33	87.46	2,551	263.65
Selling, General & Admin	576.67	571.21	499.64	402.31	376.61	341.3
Research & Development	317.41	393.27	1,336	1,331	1,407	836.32
Other Operating Expenses	51.13	-	-	-	-1.36	1.36
Operating Expenses	950.77	970.95	1,850	1,754	1,771	1,176
Operating Income	19.98	-217.2	-1,233	-1,667	779.96	-912.32
Interest Expense	-27.89	-36.39	-55.86	-39.45	-19.07	-31.88
Interest & Investment Income	51.44	52.4	89.07	8.88	3.16	2.27
Earnings From Equity Investments	-24.76	-28.44	-92.26	-262.21	-98.8	-54.57
Currency Exchange Gain (Loss)	15.99	43.22	-0.13	29.49	3.39	5
Other Non Operating Income (Expenses)	6.84	5.24	24.03	74.31	457.12	90.99
EBT Excluding Unusual Items	41.6	-181.17	-1,268	-1,856	1,126	-900.51
Gain (Loss) on Sale of Investments	-5.57	-1.52	-9.58	-16.66	10.92	-2.42
Gain (Loss) on Sale of Assets	70.27	69.27	-1.03	-	-0.25	19.95
Other Unusual Items	0.71	0.7	-	0	-	2.97
Pretax Income	107.01	-112.72	-1,279	-1,873	1,136	-880.01
Income Tax Expense	107.25	109.67	191.21	58.87	65.73	-32.63
Earnings From Continuing Operations	-0.24	-222.39	-1,470	-1,931	1,071	-847.37
Net Income to Company	-0.24	-222.39	-1,470	-1,931	1,071	-847.37
Minority Interest in Earnings	-26.25	17.7	908.77	1,256	-1,123	509.45
Net Income	-26.5	-204.69	-561.3	-675.87	-52.61	-337.92
Net Income to Common	-26.5	-204.69	-561.3	-675.87	-52.61	-337.92
Shares Outstanding (Basic)	139	139	139	139	139	139
Shares Outstanding (Diluted)	139	139	139	139	139	139
Shares Change (YoY)	-0.00%	-0.03%	0.16%	0.11%	-0.01%	0.22%
EPS (Basic)	-0.19	-1.47	-4.03	-4.86	-0.38	-2.43
EPS (Diluted)	-0.19	-1.47	-4.03	-4.86	-0.38	-2.43
Free Cash Flow	-27.98	-16.93	-541.93	-1,286	375.16	-820.23
Free Cash Flow Per Share	-0.20	-0.12	-3.89	-9.25	2.70	-5.90
Gross Margin	59.89%	54.91%	53.32%	8.28%	65.05%	42.83%
Operating Margin	1.23%	-15.82%	-106.51%	-157.87%	19.89%	-148.21%
Profit Margin	-1.64%	-14.91%	-48.48%	-64.01%	-1.34%	-54.90%
Free Cash Flow Margin	-1.73%	-1.23%	-46.81%	-121.82%	9.57%	-133.25%
EBITDA	169.3	-66.3	-1,078	-1,498	967.36	-711.59
EBITDA Margin	10.45%	-4.83%	-93.11%	-141.83%	24.66%	-115.60%
D&A For EBITDA	149.32	150.9	155.15	169.35	187.4	200.73
EBIT	19.98	-217.2	-1,233	-1,667	779.96	-912.32
EBIT Margin	1.23%	-15.82%	-106.51%	-157.87%	19.89%	-148.21%
Effective Tax Rate	100.23%	-	-	-	5.78%	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.